- Home
- BPOP vs PODD Comparison
BPOP vs PODD Comparison
Compare BPOP & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BPOP | PODD |
|---|---|---|
| Founded | 1893 | 2000 |
| Country | United States | United States |
| Employees | 9427 | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.3B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | BPOP | PODD |
|---|---|---|
| Price | $150.04 | $154.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 21 |
| Target Price | $160.18 | ★ $341.48 |
| AVG Volume (30 Days) | 407.2K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.30 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $12.86 | $24.55 |
| Revenue Next Year | $5.79 | $19.18 |
| P/E Ratio | ★ $11.87 | $120.60 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $102.00 | $145.59 |
| 52 Week High | $152.95 | $354.88 |
Technical Indicators
Market Signals| Indicator | BPOP | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 58.89 | 36.21 |
| Support Level | $141.65 | $145.59 |
| Resistance Level | $152.95 | $205.95 |
| Average True Range (ATR) | 2.97 | 7.84 |
| MACD | -0.07 | 1.77 |
| Stochastic Oscillator | 88.53 | 35.44 |
Price Performance
Historical ComparisonAbout BPOP Popular Inc.
Popular Inc, based in Puerto Rico, is a financial holding company with four main subsidiaries: Banco Popular de Puerto Rico, a bank in Puerto Rico in terms of assets; Banco Popular North America, its banking operation in the continental United States; Evertec, a data processor; and Popular Financial Holdings, a diversified financial services company. The Corporation's reportable segments consist of Banco Popular de Puerto Rico and Popular U.S.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.